Toolkit
Email Alert
Sign up to join Advicenne’s Press Releases diffusion list
Contacts
Advicenne
2, rue Briçonnet, 30 000 Nîmes, France
+33 4 66 05 54 20
investors@advicenne.com
U.S. Investor Relations
Rx Communications Group, LLC
555 Madison Ave,
New York, NY 10022, USA
+001 917-322-2216
Melody Carey mcarey@rxir.comPaula Schwartz pschwartz@rxir.com
Financial Communications
NewCap
Emmanuel Huynh & Alexia Faure
+33 1 44 71 94 94
advicenne@newcap.eu
| Firm | Analyst | Contact Details |
| Gilbert Dupont | Jamila El Bougrini | Equity Research Analyst Paris, France lifesciences@gilbertdupont.fr |
| Rx Securities | Samir Devani |
Managing Director |
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.
© 2019 Advicenne